BHV-2100 is under clinical development by Biohaven and currently in Phase I for Migraine. According to GlobalData, Phase I drugs for Migraine have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how BHV-2100’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BHV-2100 is under investigation for the treatment of neuropathic pain and migraine. It is administered by oral route. The drug candidate acts by targeting TRPM-3, a transient receptor potential cation channel subfamily M member 3.
Biohaven formerly Biohaven Research, is biopharmaceutical company discovering, developing, and commercializing novel therapies for the treatment of neurological and neuropsychiatric diseases. Biohaven is headquartered in Tortola, British Virgin Islands.
For a complete picture of BHV-2100’s drug-specific PTSR and LoA scores, buy the report here.